Ensartinib induced partial regression and disease stabilization of pulmonary epithelioid angiosarcoma lesions harboring EML4-ALK fusion after failure of multiple prior therapies in a 65-year-old patient.
Case Report (n=1)
No
Does ensartinib improve tumor response in a patient with advanced pulmonary epithelioid angiosarcoma harboring an EML4-ALK fusion?
Next-generation sequencing identified an actionable EML4-ALK fusion in a rare pulmonary epithelioid angiosarcoma, leading to a successful partial response with the ALK inhibitor ensartinib.
Epithelioid angiosarcoma is a rare type of malignant tumor that progresses rapidly and currently lacks standard and effective treatment methods. We present herein the first reported case of rare pulmonary epithelioid angiosarcoma harboring an EML4-ALK fusion, in which targeted therapy demonstrated efficacy. This advanced, unresectable epithelioid angiosarcoma continued to progress despite prior treatments, including chemotherapy, anti-angiogenic therapy, immunotherapy, and radioactive particle implantation. Given the absence of standardized treatment protocols for this malignancy, we performed next-generation sequencing (NGS) to identify potential therapeutic targets, which revealed an ALK fusion. Subsequent ALK -targeted therapy proved effective, providing novel therapeutic insights for patients with advanced, unresectable disease. Further studies are warranted to elucidate the mutational landscape of pulmonary epithelioid angiosarcoma and its implications for disease pathogenesis, progression, treatment response, and prognosis.
Gong et al. (Thu,) conducted a case report in 65-year-old man with advanced, unresectable pulmonary epithelioid angiosarcoma harboring an EML4-ALK fusion, with multiple metastases including lung, pleura, intercostal muscle, and bone (n=1). Ensartinib (ALK-targeted therapy) vs. Prior therapies including chemotherapy, anti-angiogenic therapy, immunotherapy, and radioactive particle implantation was evaluated on Tumor response assessed by chest CT (lesion size change). Ensartinib induced partial regression and disease stabilization of pulmonary epithelioid angiosarcoma lesions harboring EML4-ALK fusion after failure of multiple prior therapies in a 65-year-old patient.